 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125 when used as adjuvant treatment after completion of primary surgery and first line platinum containing chemotherapy in patients with optimally debulked 1 cm residual disease stage IIA-IIIC ovarian, fallopian tube, or primary peritoneal cancer. 